Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Short term Debt (2017 - 2025)

Aytu Biopharma (AYTU) has disclosed Short term Debt for 14 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • Quarterly Short term Debt fell 53.71% to $1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Dec 2025, down 53.71% year-over-year, with the annual reading at $9.1 million for FY2025, 388.05% up from the prior year.
  • Short term Debt for Q4 2025 was $1.9 million at Aytu Biopharma, down from $14.9 million in the prior quarter.
  • The five-year high for Short term Debt was $16.7 million in Q2 2021, with the low at $90000.0 in Q4 2022.
  • Average Short term Debt over 5 years is $4.4 million, with a median of $1.9 million recorded in 2024.
  • The sharpest move saw Short term Debt plummeted 96.55% in 2021, then skyrocketed 3205.0% in 2023.
  • Over 5 years, Short term Debt stood at $1.2 million in 2021, then tumbled by 92.54% to $90000.0 in 2022, then soared by 1040.0% to $1.0 million in 2023, then surged by 291.03% to $4.0 million in 2024, then plummeted by 53.71% to $1.9 million in 2025.
  • According to Business Quant data, Short term Debt over the past three periods came in at $1.9 million, $14.9 million, and $9.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.